<DOC>
	<DOCNO>NCT00559273</DOCNO>
	<brief_summary>This study compare efficacy safety subcutaneous Mircera subcutaneous darbepoetin treatment renal anemia participant chronic kidney disease dialysis receive erythropoiesis-stimulating agent ( ESA ) . Participants randomize receive either Mircera every 4 week , start dose 1.2 micrograms/kilogram ( mcg/kg ) , darbepoetin alfa weekly , start dose 0.45 mcg/kg ( every two week , 0.75 mcg/kg ) . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Subcutaneous Mircera Once Monthly Treatment Anemia Participants With Chronic Kidney Disease Not Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Participants chronic kidney disease ( CKD ) stage 3 ( creatinine clearance [ CrCl ] / glomerular filtration rate [ GFR ] 30 59 milliliter per minute per 1.73 meter square [ mL/min/1.73m^2 ] ) Stage 4 ( CrCl/GFR 1529 mL/min/1.73m^2 ) require dialysis . CrCl/GFR estimate CockcroftGault equation abbreviate Modification Diet Renal Disease ( MDRD ) equation Anemia define baseline Hb concentration le ( &lt; ) 10.5 gram per deciliter ( g/dL ) Previous therapy ESA within 12 week prior screen Renal allograft place Immunosuppressive therapy 12 week prior screen Overt gastrointestinal bleeding red blood cell ( RBC ) transfusion within 8 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>